Immunomic's LAMP Lights Path Toward DNA Vaccines

Privately held Immunomic Therapeutics Inc. (ITI) worked quietly for five years to advance its LAMP-vax technology, based on lysosomal associated membrane protein (LAMP), a ubiquitous glycoprotein found on 80 percent of the surface area of lysosomal membranes.